Monte Rosa Therapeutics Statistics
Share Statistics
Monte Rosa Therapeutics has 61.44M shares outstanding. The number of shares has increased by 22.5% in one year.
| Shares Outstanding | 61.44M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.1% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 45.95M |
| Failed to Deliver (FTD) Shares | 7.24K |
| FTD / Avg. Volume | 0.25% |
Short Selling Information
The latest short interest is 8.40M, so 13.68% of the outstanding shares have been sold short.
| Short Interest | 8.40M |
| Short % of Shares Out | 13.68% |
| Short % of Float | 18.19% |
| Short Ratio (days to cover) | 5.61 |
Valuation Ratios
The PE ratio is -2.15 and the forward PE ratio is -6.09.
| PE Ratio | -2.15 |
| Forward PE | -6.09 |
| PS Ratio | 0 |
| Forward PS | 13.1 |
| PB Ratio | 1.62 |
| P/FCF Ratio | -4.62 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Monte Rosa Therapeutics Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.07, with a Debt / Equity ratio of 0.
| Current Ratio | 5.07 |
| Quick Ratio | 5.07 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.76% and return on capital (ROIC) is -63.77%.
| Return on Equity (ROE) | -0.76% |
| Return on Assets (ROA) | -0.45% |
| Return on Capital (ROIC) | -63.77% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.02M |
| Employee Count | 133 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 338.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 1.09% in the last 52 weeks. The beta is 1.3, so Monte Rosa Therapeutics 's price volatility has been higher than the market average.
| Beta | 1.3 |
| 52-Week Price Change | 1.09% |
| 50-Day Moving Average | 8.11 |
| 200-Day Moving Average | 5.91 |
| Relative Strength Index (RSI) | 29.62 |
| Average Volume (20 Days) | 2.84M |
Income Statement
| Revenue | n/a |
| Gross Profit | -6.22M |
| Operating Income | -143.31M |
| Net Income | -135.35M |
| EBITDA | -137.09M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -2.63 |
Balance Sheet
The company has 128.10M in cash and 46.04M in debt, giving a net cash position of 82.06M.
| Cash & Cash Equivalents | 128.10M |
| Total Debt | 46.04M |
| Net Cash | 82.06M |
| Retained Earnings | -365.89M |
| Total Assets | 315.08M |
| Working Capital | 209.57M |
Cash Flow
In the last 12 months, operating cash flow was -43.80M and capital expenditures -19.04M, giving a free cash flow of -62.84M.
| Operating Cash Flow | -43.80M |
| Capital Expenditures | -19.04M |
| Free Cash Flow | -62.84M |
| FCF Per Share | -1.22 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
GLUE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -47.39% |
| FCF Yield | -18.43% |
Analyst Forecast
The average price target for GLUE is $11, which is 98.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $11 |
| Price Target Difference | 98.2% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Scores
| Altman Z-Score | -0.17 |
| Piotroski F-Score | 3 |